Author:
Breeur Marie,Ferrari Pietro,Dossus Laure,Jenab Mazda,Johansson Mattias,Rinaldi Sabina,Travis Ruth C.,His Mathilde,Key Tim J.,Schmidt Julie A.,Overvad Kim,Tjønneland Anne,Kyrø Cecilie,Rothwell Joseph A.,Laouali Nasser,Severi Gianluca,Kaaks Rudolf,Katzke Verena,Schulze Matthias B.,Eichelmann Fabian,Palli Domenico,Grioni Sara,Panico Salvatore,Tumino Rosario,Sacerdote Carlotta,Bueno-de-Mesquita Bas,Olsen Karina Standahl,Sandanger Torkjel Manning,Nøst Therese Haugdahl,Quirós J. Ramón,Bonet Catalina,Barranco Miguel Rodríguez,Chirlaque María-Dolores,Ardanaz Eva,Sandsveden Malte,Manjer Jonas,Vidman Linda,Rentoft Matilda,Muller David,Tsilidis Kostas,Heath Alicia K.,Keun Hector,Adamski Jerzy,Keski-Rahkonen Pekka,Scalbert Augustin,Gunter Marc J.,Viallon Vivian
Abstract
Abstract
Background
Epidemiological studies of associations between metabolites and cancer risk have typically focused on specific cancer types separately. Here, we designed a multivariate pan-cancer analysis to identify metabolites potentially associated with multiple cancer types, while also allowing the investigation of cancer type-specific associations.
Methods
We analysed targeted metabolomics data available for 5828 matched case-control pairs from cancer-specific case-control studies on breast, colorectal, endometrial, gallbladder, kidney, localized and advanced prostate cancer, and hepatocellular carcinoma nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. From pre-diagnostic blood levels of an initial set of 117 metabolites, 33 cluster representatives of strongly correlated metabolites and 17 single metabolites were derived by hierarchical clustering. The mutually adjusted associations of the resulting 50 metabolites with cancer risk were examined in penalized conditional logistic regression models adjusted for body mass index, using the data-shared lasso penalty.
Results
Out of the 50 studied metabolites, (i) six were inversely associated with the risk of most cancer types: glutamine, butyrylcarnitine, lysophosphatidylcholine a C18:2, and three clusters of phosphatidylcholines (PCs); (ii) three were positively associated with most cancer types: proline, decanoylcarnitine, and one cluster of PCs; and (iii) 10 were specifically associated with particular cancer types, including histidine that was inversely associated with colorectal cancer risk and one cluster of sphingomyelins that was inversely associated with risk of hepatocellular carcinoma and positively with endometrial cancer risk.
Conclusions
These results could provide novel insights for the identification of pathways for cancer development, in particular those shared across different cancer types.
Funder
Institut National Du Cancer
World Cancer Research Fund
European Commission
Cancer Research UK Cambridge Institute, University of Cambridge
Centre International de Recherche sur le Cancer
Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London
NIHR Imperial Biomedical Research Centre
Kræftens Bekæmpelse
Ligue Contre le Cancer
Institut Gustave-Roussy
Mutuelle Générale de l'Education Nationale
Institut National de la Santé et de la Recherche Médicale
Deutsche Krebshilfe
Deutsches Krebsforschungszentrum
Deutsche Institut für Ernährungsforschung Potsdam-Rehbrücke
Bundesministerium für Bildung und Forschung
Associazione Italiana per la Ricerca sul Cancro
Compagnia di San Paolo
Consiglio Nazionale delle Ricerche
Ministerie van Volksgezondheid, Welzijn en Sport
Nederlandse Kankerregistratie
LK Research Funds
Dutch Prevention Funds
Zorg Onderzoek Nederland
Statistics Netherlands
Instituto de Salud Carlos III
Gobierno del Principado de Asturias
Junta de Andalucía
Eusko Jaurlaritza
Comunidad Autónoma de la Región de Murcia
Gobierno de Navarra
Catalan Institute of Oncology
Cancerfonden
Vetenskapsrådet
Skåne County Council
Västerbotten Läns Landsting
Medical Research Council
Generalitat de Catalunya
Fondation ARC pour la Recherche sur le Cancer
Publisher
Springer Science and Business Media LLC